0 CHECKOUT

Chronic Plaque Psoriasis - Pipeline Review, H2 2015

  • ID: 3387888
  • July 2015
  • 125 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Almirall, S.A.
  • Cellceutix Corporation
  • Eli Lilly and Company
  • Johnson & Johnson
  • OPKO Health, Inc.
  • Sandoz International GmbH
  • MORE

Chronic Plaque Psoriasis - Pipeline Review, H2 2015

Summary

The report ‘Chronic Plaque Psoriasis - Pipeline Review, H2 2015’, provides an overview of the Chronic Plaque Psoriasis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chronic Plaque Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Plaque Psoriasis and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Almirall, S.A.
  • Cellceutix Corporation
  • Eli Lilly and Company
  • Johnson & Johnson
  • OPKO Health, Inc.
  • Sandoz International GmbH
  • MORE

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Chronic Plaque Psoriasis Overview
Therapeutics Development
Pipeline Products for Chronic Plaque Psoriasis - Overview
Pipeline Products for Chronic Plaque Psoriasis - Comparative Analysis
Chronic Plaque Psoriasis - Therapeutics under Development by Companies
Chronic Plaque Psoriasis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Chronic Plaque Psoriasis - Products under Development by Companies
Chronic Plaque Psoriasis - Companies Involved in Therapeutics Development
AbGenomics International, Inc.
Almirall, S.A.
Boehringer Ingelheim GmbH
Cellceutix Corporation
Coherus BioSciences, Inc.
Eli Lilly and Company
GlaxoSmithKline Plc
Johnson & Johnson
Mitsubishi Tanabe Pharma Corporation
Novartis AG
OPKO Health, Inc.
Pfizer Inc.
Sandoz International GmbH
Sun Pharma Advanced Research Company Ltd.
Takeda Pharmaceutical Company Limited
UCB S.A.
XenoPort, Inc.
Chronic Plaque Psoriasis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AbGn-168H - Drug Profile
Product Description
Mechanism of Action
R&D Progress
adalimumab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
adalimumab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
baricitinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BI-655066 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
C-82 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
certolizumab pegol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CJM-112 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
COVA-322 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
dimethyl fumarate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
etanercept biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
etanercept biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
etanercept biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GSK-2831781 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ixekizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KM-133 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
lunacalcipol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MT-1303 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
namilumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
orilotimod potassium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tildrakizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tofacitinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
XP-23829 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Chronic Plaque Psoriasis - Recent Pipeline Updates
Chronic Plaque Psoriasis - Dormant Projects
Chronic Plaque Psoriasis - Discontinued Products
Chronic Plaque Psoriasis - Product Development Milestones
Featured News & Press Releases
Jun 08, 2015: Pfizer Announces 12 Presentations Including New Research Data on Tofacitinib for Chronic Plaque Psoriasis and Atopic Dermatitis at World Congress of Dermatology
Feb 04, 2015: Pfizer Announces FDA Acceptance For Review Of Supplemental New Drug Application For Oral XELJANZ (tofacitinib citrate) For Adult Patients With Moderate To Severe Chronic Plaque Psoriasis
Jul 16, 2014: Coherus Announces Initiation Of Phase 3 Trial Of CHS-0214 (Investigational Etanercept Biosimilar) In Chronic Plaque Psoriasis
May 23, 2014: Pfizer Announces Detailed Results For Phase 3 OPT Retreatment Study Of Tofacitinib In Adults With Moderate-To-Severe Chronic Plaque Psoriasis
Apr 22, 2014: Pfizer Announces Positive Top-Line Results from Two Phase 3 Trials of Tofacitinib in Adults with Moderate-to-Severe Chronic Plaque Psoriasis
Mar 22, 2014: Pfizer Announces Detailed Results of OPT Compare Phase 3 Study of Tofacitinib 5 mg and 10 mg Twice Daily Compared to High-Dose ENBREL in Adults with Moderate-to-Severe Chronic Plaque Psoriasis
Mar 28, 2012: Lilly's Ixekizumab Met Primary Endpoint In Phase II Study In Patients With Chronic Plaque Psoriasis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Chronic Plaque Psoriasis, H2 2015
Number of Products under Development for Chronic Plaque Psoriasis - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Chronic Plaque Psoriasis - Pipeline by AbGenomics International, Inc., H2 2015
Chronic Plaque Psoriasis - Pipeline by Almirall, S.A., H2 2015
Chronic Plaque Psoriasis - Pipeline by Boehringer Ingelheim GmbH, H2 2015
Chronic Plaque Psoriasis - Pipeline by Cellceutix Corporation, H2 2015
Chronic Plaque Psoriasis - Pipeline by Coherus BioSciences, Inc., H2 2015
Chronic Plaque Psoriasis - Pipeline by Eli Lilly and Company, H2 2015
Chronic Plaque Psoriasis - Pipeline by GlaxoSmithKline Plc, H2 2015
Chronic Plaque Psoriasis - Pipeline by Johnson & Johnson, H2 2015
Chronic Plaque Psoriasis - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2015
Chronic Plaque Psoriasis - Pipeline by Novartis AG, H2 2015
Chronic Plaque Psoriasis - Pipeline by OPKO Health, Inc., H2 2015
Chronic Plaque Psoriasis - Pipeline by Pfizer Inc., H2 2015
Chronic Plaque Psoriasis - Pipeline by Sandoz International GmbH, H2 2015
Chronic Plaque Psoriasis - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2015
Chronic Plaque Psoriasis - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015
Chronic Plaque Psoriasis - Pipeline by UCB S.A., H2 2015
Chronic Plaque Psoriasis - Pipeline by XenoPort, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Chronic Plaque Psoriasis Therapeutics - Recent Pipeline Updates, H2 2015
Chronic Plaque Psoriasis - Dormant Projects, H2 2015
Chronic Plaque Psoriasis - Dormant Projects (Contd..1), H2 2015
Chronic Plaque Psoriasis - Discontinued Products, H2 2015

List of Figures
Number of Products under Development for Chronic Plaque Psoriasis, H2 2015
Number of Products under Development for Chronic Plaque Psoriasis - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Note: Product cover images may vary from those shown
3 of 4

AbGenomics International, Inc.
Almirall, S.A.
Boehringer Ingelheim GmbH
Cellceutix Corporation
Coherus BioSciences, Inc.
Eli Lilly and Company
GlaxoSmithKline Plc
Johnson & Johnson
Mitsubishi Tanabe Pharma Corporation
Novartis AG
OPKO Health, Inc.
Pfizer Inc.
Sandoz International GmbH
Sun Pharma Advanced Research Company Ltd.
Takeda Pharmaceutical Company Limited
UCB S.A.
XenoPort, Inc.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Merck & Co., Inc.
  • Celgene Corporation
  • GlaxoSmithKline PLC
  • Genentech, Inc.
  • Johnson & Johnson Services, Inc.
  • ViiV Healthcare